China Needs To Align With International Standards To Grow Its Biologics Industry: BIO
This article was originally published in PharmAsia News
Executive Summary
On the plus side, China has pledged policy support and hefty funding to build up its biologics industry. However, weak intellectual property protection, a challenging regulatory environment and market access and profitability issues still deter industry investment, according to the Biotechnology Industry Organization.
You may also be interested in...
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
China Biotech Podcast: BIOSECURE Updates, Genmab/ProfoundBio Deal
In this mixed Chinese- and English-language episode, guest speaker Treehill Partners co-founder Ali Pashadezah joins Brian Yang and Dexter Yan to discuss updates on the proposed BIOSECURE Act in the US Congress and US-China biotech movements. Also discussed is how Chinese biotechs are becoming acquisition targets for overseas biotech companies, including the recent purchases of Profound by Genmab and AnHeart Theraputics by Nuvantion.